INVESTORS

Press Releases

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
April 18, 2023
- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy DURHAM, N.C. --(BUSINESS WIRE)--Apr. 18, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo...
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
January 6, 2023
- FDA feedback signals the Company’s CMC plans shared are in alignment with Agency requirements and expectations - CMC regulatory feedback is a critical step in the pathway for development of azer-cel DURHAM, N.C. --(BUSINESS WIRE)--Jan. 6, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical...
Displaying 11 - 20 of 20

Investors

Investor Tools